特比萘芬与氟康唑或伊曲康唑联合治疗系统性耐药性白念珠菌感染小鼠模型研究  

Combination Therapy of Terbinafine and Fluconazole or Itraconazole in Mice Model with Systemic Infection due to Fluconazole-resistant Strains of Candida Albicans

作　　者：江惟苏[1] 刘平[1] 谭升顺[1] 江国英 张磐谏[1] 

机构地区：[1]西安交通大学第二医院皮肤科,陕西西安710004 [2]江西省中医学院附属医院检验科,江西南昌360006

出　　处：《中国皮肤性病学杂志》2005年第5期272-275,共4页The Chinese Journal of Dermatovenereology

摘　　要：目的研究特比萘芬与氟康唑或伊曲康唑联合治疗系统性耐药性白念珠菌病的疗效。方法建立小鼠系统性白念珠菌感染模型,应用特比萘芬与氟康唑或伊曲康唑联合治疗系统性白念珠菌感染。结果联合用药组小鼠的存活时间比单用药组明显延长(P<0.05),肾组织真菌计数显示联合治疗组明显低于单用药组(P<0.05)。结论特比萘芬与氟康唑或伊曲康唑联合疗法可增强抗白念珠菌效能,具有临床应用的潜能。Objective Efficacy of combined therapy with terbinafine and fluconazole or itraconazole was studied in the systemic candidiasis due to fluconazole-resistant strains of Candida albicans.Methods To establish systemic candidiasis model, animals were treated by terbinafine in conjunction with fluconazole or itraconazole.Results Terbinafine-fluconazole or itraconazole could prolong mice survival time and lower candida albicans’ colony form unit (CFU) in the kidneys than each of three drugs separately (P<0.05).Conclusion Terbinafine-fluconazole or itraconazole might enhance the beneficial antifungal effect against Candida albicans and elucidate the potential utility of the combination therapy.

关 键 词：白念珠菌 氟康唑 伊曲康唑 特比萘芬 系统性白念珠菌病 小鼠 

分 类 号：R519.3[医药卫生—内科学]